AstraZeneca’s Etcamah fails Phase 3 trial, dashing hopes for $2.9 billion breast cancer market

AstraZeneca’s oral selective estrogen receptor degrader Etcamah was evaluated in the Phase 3 SERENA-4 trial as a first-line option for patients with ER-positive, HER2-negative advanced breast cancer.

The study compared Etcamah plus Pfizer’s CDK4/6 inhibitor Ibrance against the standard combination of Ibrance and the aromatase inhibitor anastrozole. The primary endpoint was progression-free survival.

The trial did not meet its statistical goal; the improvement in progression-free survival was not significant. The result was announced on Friday, shortly after the drug received FDA approval for a different indication.

Analysts had expected a positive readout could unlock a market opportunity estimated at $2.9 billion. The failure now limits Etcamah’s growth prospects in the frontline breast-cancer space.